How Will Amplia’s $27.5M Raise Accelerate Its Pancreatic Cancer Breakthrough?

• Capital raising of approximately AUD 27.5 million via placement and share purchase plan
• Positive Phase 2a ACCENT trial interim data with superior responses over chemotherapy alone
• Lead drug Narmafotinib targets FAK, a validated cancer pathway, with orphan drug and fast track FDA designations
• Funding secured to support Phase 2b/3 pivotal trials and additional studies including ovarian cancer and kRAS inhibitor combinations